ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Aditxt Inc

Aditxt Inc (ADTX)

2.27
0.05
(2.25%)
Closed April 23 4:00PM
2.27
0.00
( 0.00% )
Pre Market: 4:32AM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
2.27
Bid
2.00
Ask
2.68
Volume
10
0.00 Day's Range 0.00
2.14 52 Week Range 68.08
Market Cap
Previous Close
2.27
Open
-
Last Trade
9
@
2.22
Last Trade Time
04:50:08
Financial Volume
-
VWAP
-
Average Volume (3m)
390,421
Shares Outstanding
1,665,214
Dividend Yield
-
PE Ratio
-0.14
Earnings Per Share (EPS)
-16.6
Revenue
934k
Net Profit
-27.65M

About Aditxt Inc

Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantatio... Aditxt Inc is a life sciences company which focuses on prolong life and enhance life quality of transplanted patients. The firm develop products designed to induce tolerance to transplanted organs. The firm's immunosuppressive (anti-rejection) drugs has made possible life-saving organ transplantation procedures as these drugs prevent or delay organ rejection. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) which utilizes tolerogenic approach that utilizes the body's natural process of cell death, to deliver a modified antigen that signals the immune system to become tolerant to transplanted tissues. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Camden, Delaware, USA
Founded
1970
Aditxt Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker ADTX. The last closing price for Aditxt was $2.27. Over the last year, Aditxt shares have traded in a share price range of $ 2.14 to $ 68.08.

Aditxt currently has 1,665,214 shares outstanding. The market capitalization of Aditxt is $3.78 million. Aditxt has a price to earnings ratio (PE ratio) of -0.14.

ADTX Latest News

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Assets include the FDA-approved LIKMEZ™, the ATI-1701 tularemia vaccine defense program that has been awarded a USD $14 million non-dilutive award from the DoD, and the ATI-1801 topical...

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023

Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023 PR Newswire SAN DIEGO, March 27, 2024 -- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced...

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy

For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy PR Newswire SAN DIEGO...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.13-5.416666666672.42.552.14394322.31506454CS
4-0.92-28.84012539183.195.452.1410062613.32564821CS
12-1.58-41.0389610393.855.452.143904213.3947185CS
26-5.95-72.38442822388.229.52.148595025.35287564CS
52-27.146-92.28311123229.41668.082.1460669110.29289105CS
156-103.33-97.8503787879105.61139.62.14227175348.94957744CS
260-208.93-98.9251893939211.21139.62.14221895472.52963666CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.2385
(56.60%)
4.55M
ZPTAZapata Computing Holdings Inc
$ 2.00
(28.21%)
1.56M
TKNOAlpha Teknova Inc
$ 2.21
(22.85%)
577
USCBUSCB Financial Holdings Inc
$ 12.80
(21.33%)
560
QTIQT Imaging Holdings Inc
$ 1.06
(19.77%)
4
EVOEvotec SE
$ 5.20
(-32.03%)
22.42k
TSDDGraniteShares ETF Trust GraniteShares
$ 28.27
(-20.37%)
9.29k
BJDXBluejay Diagnostics Inc
$ 0.50
(-20.00%)
800
TSLZT Rex 2X Inverse Tesla Daily Target ETF
$ 44.86
(-19.78%)
113.72k
KPRXKiora Pharmaceuticals Inc
$ 0.4666
(-19.48%)
6.66k
CYNCYNGN Inc
$ 0.1227
(7.63%)
4.72M
CSSEChicken Soup for the Soul Entertainment Inc
$ 0.2385
(56.60%)
4.55M
PEGYPineapple Energy Inc
$ 0.06
(6.01%)
2.24M
ZPTAZapata Computing Holdings Inc
$ 2.00
(28.21%)
1.56M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 6.45
(19.67%)
1.33M

ADTX Discussion

View Posts
Monksdream Monksdream 2 days ago
ADTX new 52 lo
👍️0
Monksdream Monksdream 1 week ago
ADTX new 52 lo
👍️0
Monksdream Monksdream 1 week ago
ADTX 10Q 4/15 per Seeking Alpha
Next day settlement begins 5/28
👍️0
plumber652 plumber652 2 weeks ago
Short sellers are paying a high cost to borrow, and have not returned the shares borrowed last week. With buying pressure and or catalyst this squeezes.
👍️0
Monksdream Monksdream 3 weeks ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
Awl416 Awl416 3 weeks ago
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
👍️0
Monksdream Monksdream 4 weeks ago
ADTX under $4
👍️0
da_stock_analyst da_stock_analyst 3 months ago
#ADTX 🔥 big move tomorrow Thursday! $ADTX
👍️0
81vette 81vette 4 months ago
Look at the news on this page,filings,the prospectus is best,very detailed about past and future events
👍️0
slicknick617 slicknick617 4 months ago
I can't find any info about and acquisition or merger. Do you have anything concrete or is it an educated guess based on previous experience ?
👍️0
81vette 81vette 4 months ago
ZERO BORROW/318% fee,I took 100%+ win to bank this time,the first big drop,scared me out lol,
👍️0
Stockexpertpro Stockexpertpro 4 months ago
VS 400K Float after 1 for 16 RS Watch for breakout above 3$ Locking in profits on ADTX Moving it to VS
👍️0
TheFinalCD TheFinalCD 4 months ago
5-7 REAL FAST

ADTX NO NEWS https://finviz.com/quote.ashx?t=ADTX&p=d


HIGH DILUTION RISK
https://dilutiontracker.com/app/search/ADTX

BUT WHAT DOES THAT MATTER THESE DAZE

??????
👍️0
81vette 81vette 4 months ago
Acq/merger in process
👍️0
ipo_dude ipo_dude 4 months ago
Whats here
👍️0
81vette 81vette 4 months ago
2nd biggest gainer in Nasdaq should bring attention
👍️0
da_stock_analyst da_stock_analyst 4 months ago
#ADTX 🔥 another big move up tomorrow? Holding 5.5! $ADTX
👍️0
81vette 81vette 4 months ago
ZERO BORROW,128%fee,something most women in the world use,it could be tradable another day or two lol,upper bolie on daily is 5.12(anything above that is parabolic)
👍️0
81vette 81vette 4 months ago
They can’t hold it down,starting to move on fewer shares again,could see .05-.10-.25 tick jumps like before,we shall see,could be down that way too lol
👍️0
81vette 81vette 4 months ago
175% win,back in now
👍️0
MiamiGent MiamiGent 4 months ago
ADTX FWIW
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173410053
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173410099
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173410265
👍️0
Awl416 Awl416 4 months ago
That happened before actually. It hit that AH August 31
👍️0
PennyPusher786 PennyPusher786 4 months ago
What? Reverse split bro. You know better lol
👍️0
subslover subslover 4 months ago
HALTED at open
👍️0
Monksdream Monksdream 4 months ago
Early Barchart 100
Wash trade
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0
subslover subslover 4 months ago
Can this possibly be true? As of November 13, 2023, the registrant had 441,902 and 441,851 shares of common stock, $0.001 par value per share, issued and outstanding, respectively.
👍️0
TheFinalCD TheFinalCD 4 months ago
that was a BS head fake break out 7.40 to 6.94 real quick
👍️0
TheFinalCD TheFinalCD 4 months ago
$ADTX did it really hit $84 August 31?????
👍️0
subslover subslover 4 months ago
NEWS
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
Evofem posted $13.4 million in net sales of Phexxi for the first nine months of 2023;

Aditxt looks to accelerate Evofem into the global non-hormonal birth control market valued at $27.7 billion in 2022 and is projected to grow to $52.2 billion by 2031

RICHMOND, Va. & SAN DIEGO--(BUSINESS WIRE)-- Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, and Evofem Biosciences, Inc. (“Evofem”) (OTCQB: EVFM), a pioneer in women’s health, today announced the signing of a definitive agreement (the “Agreement”) under which Aditxt is to acquire Evofem in consideration of the issuance of a combination of common stock and preferred stock, and the assumption of certain senior indebtedness, having an aggregate amount of approximately $100 million (the “Transaction”). Pending a successful Transaction, it will also mark the establishment of a women's health mission within Aditxt's platform, aligning with global healthcare needs.

Revolutionizing Women’s Reproductive Health with Phexxi®

Evofem is a commercial-stage women's health company with a strong focus on innovation. Evofem is the creator of the first and only FDA-approved hormone-free contraceptive gel, Phexxi® (lactic acid, citric acid, and potassium bitartrate). Phexxi® empowers women with a convenient, discreet, and flexible contraception method, putting control in their hands. By allowing on-demand usage within one hour before intercourse, Phexxi® addresses a critical need in the United States and global contraception market, offering women greater autonomy over their reproductive health decisions.

Phexxi® represents a groundbreaking shift in women's healthcare, offering a non-daily, hormone-free contraceptive choice for the 23 million women who need alternatives to traditional methods in the United States alone. Like male contraception, female contraception should be adaptable to personal needs – not a daily burden, irrespective of actual necessity. This innovation not only challenges the decades-long norm of daily hormonal contraception but empowers women with more personalized healthcare choices. Phexxi® is a testament to the urgent need for more focused innovation in women's health, ensuring choices are made for their benefit, not by chance or default.

Aditxt Unlocking Evofem’s Global Potential for Non-Hormonal Contraception

The global need for effective family planning is evident, with nearly 1.1 billion women worldwide desiring contraception, according to the UN Department of Economic and Social Affairs. This demand is mirrored in the significant market growth projections for non-hormonal birth control; Growth Plus Reports highlights an increase from $27.7 billion in 2022 to $52.2 billion by 2031. The success of Phexxi® in the U.S., with an 82% approval rate for claims and escalating sales, reflects this rising demand. With Aditxt's acquisition of Evofem, there is an opportunity to leverage this momentum, access untapped markets, and potentially capture a significant global market share. This move is poised to meet commercial objectives and address a crucial aspect of women’s healthcare. The power to decide when to have a family should rest firmly in each woman's hands, aligning with her life choices and aspirations and thus playing a crucial role in shaping her economic and social future.

Furthermore, Evofem's consistent sales growth aligns with the rising demand for innovative contraceptive solutions. The post-acquisition integration into the Aditxt platform will strengthen Evofem's ability to enter global markets through organic expansion, product acquisitions, and licensing agreements, positioning it to capture a substantial market share and address crucial women's healthcare needs globally.

Aditxt – A Platform for Accelerating Promising Innovations

As a company focused on discovering, developing, and deploying promising health innovations, Aditxt offers a dynamic environment dedicated to helping ground-breaking innovations thrive. As a public company with global stakeholders, Aditxt aims to engage society in supporting innovations addressing autoimmunity, health by the numbers, life-extending transplant technologies, population health, and now, with the proposed Evofem acquisition, women’s health, rendering its collaborative ecosystem a powerful tool for realizing the full potential of each subsidiary.

Amro Albanna, co-Founder, chairman, and CEO of Aditxt, shared his insights on this announcement: “At Aditxt, our mission is to make promising innovations possible together. Evofem represents precisely the kind of groundbreaking innovation that aligns with our mission. Aditxt will provide Evofem with a global platform to amplify their transformative innovation in women’s health. As we move forward, we aim to empower our shareholders to participate in this journey through their votes. This approach ensures that our stakeholders are integral in advancing these vital health innovations on the Aditxt platform, truly socializing how health innovations advance and impact lives worldwide.”

“We are excited about the opportunity to accelerate our growth trajectory, as a subsidiary of Aditxt, into a multi-product women’s health franchise,” said Evofem’s CEO, Saundra Pelletier. “We believe this Transaction is in the best interests of our shareholders and are confident that they and the women we serve will benefit from our expanded offering and stronger voice.”

Details of the Proposed Transaction

The Transaction is intended to create significant strategic advantages for both companies. Evofem’s growing revenue base may allow Aditxt to catalyze future growth by leveraging synergies by and amongst Evofem, Aditxt, and Aditxt’s other subsidiaries. The boards of directors of both companies have unanimously approved the Transaction.

Aditxt has assumed Evofem’s senior secured debt that was issued to the investor under the Securities Purchase and Security Agreement dated April 2020, as amended, and shall pay $5.0 million to Evofem’s senior secured debtholder by year-end 2023, $8.0 million by September 2024, and up to an additional $5 million thereafter.

Aditxt has also agreed to provide a $3.0 million loan to Evofem between the date of signing of the Agreement and closing and to cover Evofem’s legal costs related to the Transaction. At closing, the holders of Evofem’s common stock will exchange their shares for an aggregate of 610,000 shares of Aditxt common stock. In addition, Aditxt has agreed to issue up to an aggregate of 89,126 shares of preferred stock to the holders of Evofem’s currently outstanding unsecured notes, purchase rights, certain warrants, and preferred stock. Upon closing of the Transaction, which is currently anticipated to occur in the first half of 2024, Evofem will be a wholly owned subsidiary of Aditxt, with the Evofem management team to receive equity grants in the subsidiary of up to ten percent on a fully diluted basis after closing, and will continue to be led by Saundra Pelletier, Chief Executive Officer of Evofem, and the current management team.

The boards of directors of Aditxt and Evofem have unanimously approved the proposed Transaction. The Transaction is subject to, among other things, the approval of both Aditxt and Evofem stockholders and satisfaction or waiver of the conditions stated in the Agreement.

The description of the business combination contained herein is only a high-level summary. Additional information about the proposed Transaction, including a copy of the business combination agreement, will be provided in a Current Report on Form 8-K to be filed by Aditxt with the Securities and Exchange Commission ("SEC") and will be available at the SEC's website at www.sec.gov. In addition, Aditxt intends to file a registration statement on Form S-4 with the SEC, which will include a proxy statement/prospectus and will file other documents regarding the proposed Transaction with the SEC.

About Aditxt, Inc.

Aditxt is focused on discovering, developing, and deploying life-changing health innovations. Aditxt’s diverse portfolio includes Adimune™, Inc., developing a new class of therapeutics designed to retrain the immune system to address organ rejection, autoimmunity, and allergies; and Pearsanta™, Inc., offering timely, convenient, and high-quality personalized lab testing anytime and anywhere, backed by its CLIA-certified and CAP-accredited monitoring center. For more information, visit Aditxt.com.

About Evofem Biosciences, Inc.

Evofem is focused on commercializing innovative products to address unmet needs in women's sexual and reproductive health. The Company’s first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. Learn more at phexxi.com and evofem.com.

Aditxt® is a registered trademark and Adimune™, Adivir™, and Pearsanta™ are trademarks of Aditxt, Inc.

Phexxi® is a registered trademark of Evofem Biosciences, Inc.

Sources

United Nations Department of Economic and Social Affairs, Population Division (2022). World Family Planning 2022: Meeting the changing needs for family planning: Contraceptive use by age and method. UN DESA/POP/2022/TR/NO. 4. Accessed 29 November 2023 via https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/files/documents/2023/Feb/undesa_pd_2022_world-family-planning.pdf
Growth Plus Reports. Non-Hormonal Birth Control Market by Type (Contraceptive Devices, Sterilization), Gender (Male, Female) – Global Outlook & Forecast 2023-2033. 05 May 2023. Accessed 28 November 2023 via https://www.growthplusreports.com/report/nonhormonal-birth-control-market/8914
Additional Information and Where to Find It

In connection with the Agreement and the proposed Transaction, Aditxt intends to file with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “Registration Statement”), which will include a joint preliminary proxy statement/prospectus certain other related documents; this will be both the proxy statement to be distributed to the respective stockholders of Aditxt and Evofem in connection with Aditxt’s and Evofem’s solicitation of proxies for the vote by their respective stockholders with respect to the proposed Transaction and other matters as may be described in the definitive proxy statement. This press release does not contain any information that should be considered by Aditxt’s or Evofem’s stockholders concerning the proposed Transaction and is not intended to constitute the basis of any voting or investment decision in respect of the proposed Transaction. The respective stockholders of Aditxt and Evofem and
👍️0
TheFinalCD TheFinalCD 4 months ago
https://finviz.com/quote.ashx?t=ADTX&ty=c&ta=1&p=d
https://dilutiontracker.com/app/search/ADTX
👍️0
Awl416 Awl416 4 months ago
Aditxt, Inc. Enters into Definitive Agreement to Acquire Evofem Biosciences, Inc., Creator of Phexxi®, the First and Only FDA-Approved Hormone-Free Contraceptive Gel, to Address Diverse Reproductive Health Needs of Women Globally
👍️0
81vette 81vette 5 months ago
500%win 3 months ago,more watcher’s now!!
👍️0
WARHAMMER WARHAMMER 5 months ago
Sweet pump and dump right here, lol at the smoldering embers, good pump fellas.
👍️0
green maschine green maschine 5 months ago
Good morning all. Looks like fun times here.
👍️0
dinogreeves dinogreeves 5 months ago
Yup, nice little score. Thanks.
🕳️ 1 🪦 1 ☠️ 1 ⚰️ 1 ⚱️ 1
Awl416 Awl416 5 months ago
Lol
👍️0
subslover subslover 5 months ago
HUGE CALL dino!
👍️0
dinogreeves dinogreeves 5 months ago
Could be running hard soon.
💩 1 🕳️ 1 🤡 1 🪦 1 ⚰️ 1
Monksdream Monksdream 5 months ago
ADTX new 52 week low
👍️0
Monksdream Monksdream 5 months ago
ADTX new 52 low
👍️0
Stockexpertpro Stockexpertpro 5 months ago
ADTX Watch for a breakout above 5$ Next AIRE
👍️0
Awl416 Awl416 7 months ago
Nice
👍️0
Zardiw Zardiw 8 months ago
+++ #DDAmanda Chart on: $ADTX :

DDAmanda lets you find these b4 they run:



Z
👍️ 1
halbroke1 halbroke1 8 months ago
ADTX $$$ THE MAJORITY ARE SAYING HUGE FIREWORKS NEXT WEEK OVER AT STOCKTWITS, POSSIBLY A BIGGER MOVE THAN H*KD...WOW!!!..SH*RTS ARE REALLY TRAPPED ON A 190K FLOAT..WOW.
👍️0
Pt3 Pt3 8 months ago
I'm not in yet so no 500 no hkd
👍️0
TheFinalCD TheFinalCD 8 months ago
https://dilutiontracker.com/app/search/ADTX?a=dbb88c
👍️0
Awl416 Awl416 8 months ago
Fun to watch I will say. What’s that halt number 7?
👍️0
halbroke1 halbroke1 8 months ago
ADTX $$$ COULD SEE AN EASY $500+ HERE.....REMINDS ME OF H*KD...
👍️0
KeepItRealistic KeepItRealistic 8 months ago
$ADTX interesting

$ADTX and $DBGI both had private funding news by same agent todayhttps://t.co/1Cj6iS8pw3https://t.co/ZJWbulS6oA pic.twitter.com/qBMjF6zImc— KIR (@KeepRealistic) September 1, 2023
👍️0
Zardiw Zardiw 8 months ago
+++ #DDAmanda Chart on: $ADTX :

DDAmanda lets you find these b4 they run:



Z
👍️0

Your Recent History

Delayed Upgrade Clock